Himachal Pradesh News
47 Drug Samples Fail Quality Test in India: Himachal Pradesh Pharma Units Under Scanner
Concerns over drug safety have intensified after 47 medicine samples manufactured in Himachal Pradesh were declared substandard, raising serious questions about quality control in one of India’s key pharmaceutical hubs.
Concerns over drug safety have intensified after 47 medicine samples manufactured in Himachal Pradesh were declared substandard, raising serious questions about quality control in one of India’s key pharmaceutical hubs.
The findings were part of a monthly drug alert released by the Central Drugs Standard Control Organisation (CDSCO), which revealed that 141 drug samples across the country failed to meet prescribed quality standards.
Commonly Used Medicines Among Failed Samples
What has alarmed both regulators and the public is that the list includes widely used medicines such as antibiotics, painkillers, and anti-allergy drugs. These include:
- Amoxicillin and potassium clavulanate tablets
- Diclofenac potassium
- Paracetamol and chlorzoxazone
- Telmisartan (used for blood pressure)
- Cefixime, metronidazole
- Rabeprazole sodium
- Pregabalin and methylcobalamin
- Levocetirizine tablets
- Pre- and probiotic capsules
These medicines are commonly prescribed for conditions ranging from infections and inflammation to hypertension, allergies, and chronic pain—making the issue particularly concerning for everyday patients.
Serious Lapses Found in Manufacturing
In one of the most worrying cases, a Nalagarh-based pharmaceutical unit producing sterile water for injection failed sterility tests, raising red flags about its production practices.
Additionally, several injectable drugs were found to be substandard. A diclofenac sodium injection failed identification tests and showed reduced potency. Even povidone-iodine solution, widely used for wound care and surgical disinfection, was found lacking in its active content.
What Went Wrong?
Laboratory analysis pointed to multiple critical failures, including:
- Poor dissolution (drug not dissolving properly)
- Incorrect active ingredient levels
- Lack of uniformity in content
- pH imbalance
- Microbial contamination
- Sterility failures in injectables
- Mislabeling and substandard composition
Health experts warn that such defects can reduce the effectiveness of medicines or even pose health risks, especially in serious conditions.
Regulatory Action Begins
State Drug Controller Manish Kapoor has confirmed that strict action will be taken. Notices will be issued to all manufacturers whose products failed the tests, and they will be required to recall affected batches immediately.
Authorities have also directed Assistant Drug Controllers to conduct joint inspections of manufacturing units, particularly those with repeated violations.
“No compromise on quality in pharmaceutical manufacturing will be tolerated,” Kapoor stated, signaling a zero-tolerance approach.
Himachal’s Pharma Industry Under Pressure
The affected drug samples were manufactured in key pharmaceutical zones such as Baddi-Barotiwala-Nalagarh, Una, Parwanoo, Kala Amb, Kangra, and Paonta Sahib—regions that form the backbone of Himachal Pradesh’s pharma industry.
With India being one of the world’s largest suppliers of generic medicines, such quality failures not only impact domestic healthcare but can also affect global trust.
